Organ Doses Research Articles

Clinical impact of DVH uncertainties

Dose-volume histograms (DVH), along with dose and volume metrics, are central to radiotherapy planning. As such, errors have the potential to significantly impact the selection of appropriate treatment plans. Dose distributions that pass tests in one TPS may fail the same tests when transferred to another, even if using identical structures and dose grid information. This work shows the design and implementation of methods for assessing the accuracy of dose and volume computations performed by treatment planning systems (TPS), and other analytical tools. We demonstrate examples where differences in calculations between systems can change the assessment of a plan’s clinical acceptability. Our work also provides a more detailed DVH analysis of single targets than earlier published studies. This is relevant for SRS plans and small structure dose assessments. Very small structures are a particular problem because of their coarse digital representation, and the impact of this is thoroughly examined.Reference DVH curves were derived mathematically, based on Gaussian dose distributions centered on spherical structures. The structures and dose distributions were generated synthetically, and imported into RayStation, MasterPlan, and ProKnow. Corresponding DVHs were analytically derived and taken as ground truth references, for comparison with the commercial DVH calculations. Two commonly used dose metrics PCI and MGI were used to determine the limit of calculation accuracy for small structures. In addition, to measure the DVH differences between a larger range of commercial DVH calculators, the D95 metric from a set of real clinical plans was compared across both the 3 DVH calculators under test, and across a further six TPSs from other hospitals.We show that even slight deviations between the results of DVH calculators can lead to plan check failures, and we illustrate this with the commonly used D95 planning metric. We present clinical data across eight planning systems that highlight instances where plan checks would pass in one software and fail in another due to DVH calculation differences. For the smallest volumes tested, errors of up to 20% were observed in the DVHs. RayStation was tested down to a 3 mm radius sphere (≈0.1 cc) and this showed close to 10% error, reducing to 1% for 10 mm radius (≈4.0 cc) and 0.1% for 20 mm radius (≈33 cc). In clinical plans, the variation in D95 was up to 9% for the smallest volumes, and typically around 2% in the range 0.5 cc-20 cc, and 1% in 20 cc-70 cc, falling to <0.1% for large volumes. Paddick Conformity Index (PCI) and Modified Gradient Index (MGI) are commonly used plan quality indicators for very small volumes. For volumes ≈0.1 cc we observed errors of up to 40% in PCI, and up to 75% in MGI.Our study extends the range of tested DVH calculators in published work, and shows their performance over a wider range of volume sizes. We provide quantitative evidence of the critical need to test the accuracy of DVH calculators in the TPS before clinical use. This work is particularly relevant for both stereotactic plan evaluation and for assessment of small volume doses in published dose constraint recommendations. We demonstrate that significant errors can occur in DVHs for volumes less than 1 cc, even if the volumes themselves are calculated accurately. Even for large structures, deviations between the outputs of DVH calculators can lead to indicated or reported plan check failures if they do not include appropriate tolerances. We urge caution in the use of DVH metrics for these very small volumes and recommend that appropriate DVH uncertainty tolerances are set in organ dose constraints when using them to evaluate clinical plans.

Machine Learning for Predicting Neutron Effective Dose

The calculation of effective doses is crucial in many medical and radiation fields in order to ensure safety and compliance with regulatory limits. Traditionally, Monte Carlo codes using detailed human body computational phantoms have been used for such calculations. Monte Carlo dose calculations can be time-consuming and require expertise in different processes when building the computational phantom and dose calculations. This study employs various machine learning (ML) algorithms to predict the organ doses and effective dose conversion coefficients (DCCs) from different anthropomorphic phantoms. A comprehensive data set comprising neutron energy bins, organ labels, masses, and densities is compiled from Monte Carlo studies, and it is used to train and evaluate the supervised ML models. This study includes a broad range of phantoms, including those from the International Commission on Radiation Protection (ICRP-110, ICRP-116 phantom), the Visible-Human Project (VIP-man phantom), and the Medical Internal Radiation Dose Committee (MIRD-Phantom), with row data prepared using numerical data and organ categorical labeled data. Extreme gradient boosting (XGB), gradient boosting (GB), and the random forest-based Extra Trees regressor are employed to assess the performance of the ML models against published ICRP neutron DCC values using the mean square error, mean absolute error, and R2 metrics. The results demonstrate that the ML predictions significantly vary in lower energy ranges and vary less in higher neutron energy ranges while showing good agreement with ICRP values at mid-range energies. Moreover, the categorical data models align closely with the reference doses, suggesting the potential of ML in predicting effective doses for custom phantoms based on regional populations, such as the Saudi voxel-based model. This study paves the way for efficient dose prediction using ML, particularly in scenarios requiring rapid results without extensive computational resources or expertise. The findings also indicate potential improvements in data representation and the inclusion of larger data sets to refine model accuracy and prevent overfitting. Thus, ML methods can serve as valuable techniques for the continued development of personalized dosimetry.

Survey of Radiological Parameters at a Dumpsite Near an Oil and Gas Facility in Bayelsa State, Nigeria

The issue of proper waste management is becoming more critical with the increase of civilization and urbanization. Waste generation and disposal could increase levels of human radiation exposure. The dose rates from possible radioactive materials at Gbaraun-toru dumpsite have been investigated. Radiation survey meter was used to assess the dose rates at the site. Model equations were also used to estimate the health-related radiological parameters for the flux of scavengers and individuals using the dump site. The values of the measured dose rates at the dumpsites lie between (0.01 – 0.016) mRh-1 with a mean of 0.013 mRh-1. Absorbed dose rates and equivalent dose rates estimated ranged from (87.4 – 139.4) with a mean of 116.2 and (0876 – 1.402) with a mean of 1.113 . Annual effective dose rates, organ doses, and the excessive lifetime risk of cancer ranged from (0.357– 0.572) with mean 0.454 mSvy-1, (0.139 – 0.248) and (0.94 – 1.54) × 10-6 with mean of 1.28 × 10-6 respectively. Conclusively, the estimated absorbed measured rates for the study are above the safe limit (54 nGyh-1), while, others are within the safe limit (1 mSvh-1). This suggests that there may be an increment in the level of exposure of the workers at the dump sites, hence, regular radiological studies should be carried out in the study area

Patient organ dose during multicycle radiation dosimetry in Lutetium −177 radionuclide therapy

Precise patient radiation dosimetry during theranostic procedures allows clinicians to tailor therapeutic procedures to each patient. Organ dose measurement aids in adjustment of the administered activity or number of treatment cycles to maximize tumor cell destruction while minimizing damage to healthy tissues. This study was aimed at quantifying patient organ doses during Lu-177 DOTATATE and Lu-177 PSMA theranostic procedures. Nine patients underwent Lu-177 radionuclide therapy, usually four cycles with 6–8 GBq administered activity per cycle. The typical dose is 7.5 GBq as a fixed activity. Using quantitative dosimetry, physicians can estimate the next dose cycle according to patient condition. The average dose per activity for critical organs were low, at 1.76, 1.96, 0.25, 0.5, and 2.43 mSv/MBq for the right kidney, left kidney, liver bladder, and spleen, respectively. The doses for the left and right kidneys, liver, urinary bladder, and spleen were lower than those in previously published studies. Wide variations were observed in patient organ doses for Lu-177 DOTATATE and Lu-177 PSMA procedures. Further studies are recommended to ensure organ safety during theransotic procedures, to minimize the radiogenic risks to healthy organs.

Estimation of Organ Doses in Pediatric Patients for Different Imaging Protocols and Examinations

In this study, the Volume Computed Tomography Dose Index (CTDIvol) Dose Length Product (DLP), effective patient doses (ED), and organ doses were calculated for pediatric patients aged 0, 1, 5, and 10 years undergoing computed tomography (CT) examinations using the VirtualDose program, a software designed for reporting such doses. The study utilized a Toshiba Aquilion 16 CT scanner. Head, chest, and pelvis CT scans were simulated with commonly used kVp, mAs, and pitch values. The results indicated a significant difference in organ doses between standard and low-dose protocols. When kVp and mAs values were increased, ED and organ doses increased by an average of 2.5 times. Conversely, when kVp and mAs values were held constant and pitch value was increased, ED and organ doses decreased by an average of 2 times. Physicians requesting pediatric CT scans should continuously evaluate the requested examinations based on their benefits and risks. To reduce organ doses, scanning protocols should be reviewed, and low-dose protocols should be preferred. Additionally, newer generation devices that provide lower dose scanning should be utilized.

Comparison of Lung and Contralateral Scattered Breast Dose between Field-in-Field and Wedge Techniques in Patients with Early Breast Cancer

Purpose: This study aims to evaluate the dosimetric result of the Field-In-Field (FIF) plans compared with Tangential Wedged Beams (TWB) plans for whole breast radiotherapy of patients. Materials and Methods: In this survey, we entered fifty patients with breast-conserving surgery and postoperative whole-breast radiotherapy. FIF and a TWB plan were made for each patient to compare dosimetric outcomes. Results: The Homogeneity Index (HI) and Conformity Index (CI) were specified for the evaluation of Planning Target Volume (PTV). The mean dose of the ipsilateral lung and contra-lateral breast for the evaluation of organs at risk dose were used. The FIF plans had significantly lower HI (p &lt; 0.01) and CI (p &lt; 0.01) than those of the TWB plans. It means in the dosimetric comparisons of the PTV, the FIF plans were better than the TWB plans. The V10lung (31.152vs. 32.72%, p &lt; 0.01), V20lung (25.6064vs. 26.6%, p &lt; 0.01) V30lung (17.4% vs. 18.4%, p &lt; 0.01) were lower with the FIF plans compared with those of the TWB plans, with statistical significance. The FIF plans had a lower mean dose for the lung than those of TWB plans (1225.48 vs. 1670.32 cGy) but no statistical significance (p=0.06). The mean dose in the contra-lateral of the breast in FIF plans was lower than in TWB plans (61.666 vs. 163.45 cGy), with statistical significance (p &lt; 0.01). Conclusion: The FIF plans increased the dose homogeneity, and conformity of the target volume for the whole-breast irradiation compared with the TWB plans. Moreover, the doses of organs at risk (ipsilateral lung and contralateral breast) were reduced with FIF plans.

Assessment of radiation exposure risks in patients undergoing elastic stable intramedullary nailing: Insights from intraoperative fluoroscopy

IntroductionElastic stable intramedullary nailing (ESIN) is a well-defined and appropriate treatment of choice for long bone fractures. Despite its benefits, the risk of cancer from imaging devices is of particular concern for younger adults. So, this survey was conducted to estimate the doses administered to patients undergoing ESIN of long bone fractures utilizing a 2-dimensional (2D) C-arm fluoroscopy machine during surgery, as well as the carcinogenic risk associated with the use of the machine. MethodsThis study was conducted on 147 patients who required ESIN for long-bone fractures. Patients' demographic data, surgical data and imaging information were collected. For each patient, the organ doses and the effective doses were computed with the Monte Carlo PCXMC 2.0 simulation software. The cancer risk models proposed in the Biological Effects of Ionizing Radiation VII (BEIR VII) Phase 2 report were used to evaluate the risk of exposure-induced cancer death (REID) values. ResultsFor all patients, the highest organ dose was delivered to the gonads. The mean effective dose was 0.026 ± 0.015 mSv and 1.3E-04 ± 1E-04 mSv for ESIN of femur and tibia fractures, respectively. Males had a mean REID of 1 per million, while females had a mean REID of 0.19 per million. The younger males had considerably higher REID values. The effective dose was significantly correlated with age, gender, and irradiation time. ConclusionLow levels of effective doses and cancer risks associated with the utilization of the fluoroscopy machine in current practice were found in ESIN treatment of long-bone fractures. Implications for practiceThis outcome will help to raise surgeons' awareness of radiation risks and encourage them to initiate measures to keep radiation dose and exposure time as low as reasonably achievable.

Patient-specific radiation dose for Chinese pediatric patients undergoing whole-body PET/CT examinations

Objective. To assess potential variations in the absorbed dose between Chinese and Caucasian children exposed to 18F-FDG PET scan and to investigate the factors contributing to dose differences, this work employed patient-specific phantoms and our compartment model for calculating the patient-specific absorbed dose in Chinese children. Approach. Data of 29 Chinese pediatric patients undergoing whole-body 18F-FDG PET/CT studies were retrospectively collected, including PET images for activity distributions and corresponding CT images for organ segmentation and phantom construction. A biokinetic compartment model was implemented to obtain cumulated activities. Absorbed radiation dose for both CT and PET component were calculated using Monte Carlo simulations. Regression models were fitted to time integrated activity coefficient (TIAC) and organ absorbed dose for each patient. Main results. TIACs of all the organs in our compartment model and the organ dose for 12 organs were correlated with patients’ weight. Young children have significantly large uptake in brain compared to adults. The distinctions of anatomical and biological characteristics between Chinese and Caucasian children contribute to variations in the absorbed dose of 18F-FDG PET scans. PET contributed more in organ dose than CT did in most organs, especially in brain and bladder. The average effective dose (± SD) was 4.5 mSv (± 1.12 mSv), 7.8 mSv (± 3.2 mSv) and 12.3 mSv (± 3.5 mSv) from CT, PET and their sum respectively. PET contributed 1.7 times higher than CT. Significance. To the best of our knowledge, this work represents the first attempt to estimate patient-specific radiation doses from PET/CT for Chinese pediatric patients. TIACs derived from our methodology in both age groups exhibited significant differences from the that reported in ICRP 128. Substantial differences in absorbed and effective doses were observed between Chinese and Caucasian children across all age groups. These disparities are attributed to markedly distinct anatomical and pharmacokinetic characteristics among adults and pediatric patients, and different racial groups. The application of data derived from adults to pediatric patients introduces considerable uncertainty. Our methodology offers a valuable approach not only for estimating pharmacokinetic characteristics and patient-specific radiation doses in pediatric patients undergoing 18F-FDG studies but also for other cohorts with similar characteristics.

Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).

PET/CT imaging with Zirconium-89 labeled [89Zr]Zr-DFO-girentuximab, which targets tumor antigen CAIX, may aid in the differentiation and characterization of clear cell renal cell carcinomas (RCC) and other renal and extrarenal lesions, and has been studied in European and American cohorts. We report results from a phase I study that evaluated the safety profile, biodistribution, and dosimetry of [89Zr]Zr-DFO-girentuximab in Japanese patients with suspected RCC. Eligible adult patients received 37MBq (± 10%; 10mg mass dose) of intravenous [89Zr]Zr-DFO-girentuximab. Safety and tolerability profile was assessed based on adverse events, concomitant medications, physical examination, vital signs, hematology, serum chemistry, urinalysis, human anti-chimeric antibody measurement, and 12-lead electrocardiograms at predefined intervals. Biodistribution and normal organ and tumor dosimetry were evaluated with PET/CT images acquired at 0.5, 4, 24, 72h and Day 5±2d after administration. [89Zr]Zr-DFO-girentuximab was administered in six patients as per protocol. No treatment-emergent adverse events were reported. Dosimetry analysis showed that radioactivity was widely distributed in the body, and that the absorbed dose in healthy organs was highest in the liver (mean±standard deviation) (1.365±0.245mGy/MBq), kidney (1.126±0.190mGy/MBq), heart wall (1.096±0.232mGy/MBq), and spleen (1.072±0.466mGy/MBq). The mean effective dose, adjusted by the radioactive dose administered, was 0.470mSv/MBq. The radiation dose was highly accumulated in the targeted tumor, while any abnormal accumulation in other organs was not reported. This study demonstrates that [89Zr]Zr-DFO-girentuximab administered to Japanese patients with suspected RCC has a favorable safety profile and is well tolerated and has a similar dosimetry profile to previously studied populations.

Dose, dose, dose, but where is the patient dose?

The article reviews the historical developments in radiation dose metrices in medical imaging. It identifies the good, the bad, and the ugly aspects of current-day metrices. The actions on shifting focus from International Commission on Radiological Protection (ICRP) Reference-Man-based population-average phantoms to patient-specific computational phantoms have been proposed and discussed. Technological developments in recent years involving AI-based automatic organ segmentation and 'near real-time' Monte Carlo dose calculations suggest the feasibility and advantage of obtaining patient-specific organ doses. It appears that the time for ICRP and other international organizations to embrace 'patient-specific' dose quantity representing risk may have finally come. While the existing dose metrices meet specific demands, emphasis needs to be also placed on making radiation units understandable to the medical community.

Radiation doses and diagnostic reference levels for common CT scans in adults in Northwest region of Iran.

This study aims to estimate organ dose and cancer risks, establish region-specific diagnostic reference levels (DRLs), and determine achievable doses (ADs) for common CT procedures in adults in the northwest of Iran. Effective and organ doses were estimated using VirtualDoseCT software in a sample of 480 adult patients who underwent head, sinus, chest, and abdomen-pelvis (AP) CT scans. The guidelines provided by the BEIR VII report were utilized to estimate cancer risks. Effective and organ doses for specific procedures were determined, with the highest mean organ dose being observed in the brain during head CT examinations, with a value of 54.02mGy. It was observed that the lungs in chest examinations and the colon in AP examinations had the highest risk of cancer, with rates of 30.72 and 21.37 per 100,000 persons, respectively. Higher cancer risk values were generally exhibited by females compared to males. The DRLs for common CT examinations were established as follows: Head CT (CTDIvol 41 mGy, DLP 760 mGycm), Sinus CT (CTDIvol 16 mGy, DLP 261 mGycm), Chest CT (CTDIvol 8 mGy, DLP 287 mGycm), and AP CT (CTDIvol 9 mGy, DLP 508mGycm). Significant variations in dose distribution among facilities were identified, indicating the need for optimization. The study highlights the importance of minimizing radiation exposure to critical organs and promoting patient safety in CT examinations. The establishment of region-specific DRLs and ADs can help optimize radiation doses and reduce cancer risks for patients.

Cone beam CT doses in radiotherapy patient positioning in Finland-prostate treatments.

Imaging parameters, frequencies and resulting patient organ doses in treatments of prostate cancer were assessed in Finnish radiotherapy centres. Based on a questionnaire to the clinics, Monte Carlo method was used to estimate organ doses in International Commission on Radiological Protection standard phantom for prostate, bladder, rectum and femoral head. The results show that doses from cone beam computed tomography imaging have reduced compared to earlier studies and are between 3.6 and 34.5mGy per image for the above-mentioned organs and for normal sized patients. There still is room for further optimization of the patient exposure, as many centres use the default imaging parameters, and the length of the imaged region may not be optimal for the purpose.

Dosimetry of lutetium-177-PSMA-I&amp;T radioligand therapy in recurrent/metastatic adenoid cystic carcinoma.

6093 Background: There is a high unmet need for effective systemic therapies for recurrent and/or metastatic (R/M) adenoid cystic carcinoma (AdCC), as no standard-of-care exists. AdCC frequently expresses prostate-specific membrane antigen (PSMA), providing rationale for PSMA-targeted therapies, which have demonstrated significant efficacy in prostate cancer. In our phase 2 pilot trial (EudraCT 2019-003857-27), we assessed the safety, efficacy and feasibility of lutetium-177 (177Lu)-PSMA-I&amp;T in R/M AdCC patients. Despite well-tolerated, the efficacy was limited. To gain further insight into causes of the limited efficacy, we measured absorbed 177Lu-PSMA-I&amp;T radiation doses in tumors and organs at risk. Methods: Dosimetry was feasible and was performed in all 10 enrolled AdCC patients. They received 177Lu-PSMA-I&amp;T with a median activity of 7.40 (range 6.78-7.49) GBq and a median of 4 (range 1-4) cycles. For bone marrow dosimetry, blood samples were collected during cycle 1. Single-photon emission CT/CT (SPECT/CT) was performed at 1, 24, 48, 72 and 168 hours after 177Lu-PSMA-I&amp;T injection at cycle 1. Tumors &gt;1 cm were categorized based on gallium-68 (68Ga)-PSMA PET mean standardized uptake value (SUVmean): above, at (±10%), and below liver SUVmean. Per site, up to 3 index lesions per category were selected. Volumes of interest with ~1 cm margin were drawn on SPECT/CT. Background correction was applied. Salivary gland and bone lesion volume were determined by iterative thresholding on 68Ga-PSMA PET. Other tumor volumes were determined on CT. Hermes dosimetry software and Olinda 2.2 software were used to estimate doses according to the Medical Internal Radiation Dose scheme. Results were reported as the absorbed dose at cycle 1 (Gy). Results: In total, 66 tumor lesions were analyzed. Tumor sites included lung (n=35), pleura (n=16), liver (n=5), bone (n=4), lymph node (n=3), local recurrence (n=2) and thoracic wall (n=1). The median 68Ga-PSMA PET tumor/liver SUVmean ratio was 0.94 (range 0.33-2.62). The median tumor-absorbed dose was 0.47 (range, 0.01-4.66) Gy. Highest median doses by tumor site were 1.84 (range, 0.76-2.92) Gy in local recurrences and 1.35 (range, 0.33-2.62) Gy in bone lesions. Lowest median doses by tumor site were 0.18 (range, 0.14-0.27) Gy in lymph node lesions and 0.21 (range, 0.12-0.79) Gy in liver lesions. In organs at risk, the absorbed dose was highest in the kidneys, followed by the salivary glands, with mean values of 6.29 (standard deviation [SD], 2.32) Gy and 5.07 (SD, 2.47) Gy, respectively. The mean bone marrow absorbed dose was 0.53 (SD, 0.14) Gy. Conclusions: Tumor-absorbed radiation doses in our AdCC patient cohort receiving 177Lu-PSMA-I&amp;T were significantly lower than in prostate cancer (~10-40 Gy per cycle), likely due to lower and heterogeneous PSMA expression. This could explain the limited efficacy. Organ-absorbed doses aligned with studies in prostate cancer. Clinical trial information: NCT04291300 .

PND-Net: Physics-Inspired Non-Local Dual-Domain Network for Metal Artifact Reduction.

Metal artifacts caused by the presence of metallic implants tremendously degrade the quality of reconstructed computed tomography (CT) images and therefore affect the clinical diagnosis or reduce the accuracy of organ delineation and dose calculation in radiotherapy. Although various deep learning methods have been proposed for metal artifact reduction (MAR), most of them aim to restore the corrupted sinogram within the metal trace, which removes beam hardening artifacts but ignores other components of metal artifacts. In this paper, based on the physical property of metal artifacts which is verified via Monte Carlo (MC) simulation, we propose a novel physics-inspired non-local dual-domain network (PND-Net) for MAR in CT imaging. Specifically, we design a novel non-local sinogram decomposition network (NSD-Net) to acquire the weighted artifact component and develop an image restoration network (IR-Net) to reduce the residual and secondary artifacts in the image domain. To facilitate the generalization and robustness of our method on clinical CT images, we employ a trainable fusion network (F-Net) in the artifact synthesis path to achieve unpaired learning. Furthermore, we design an internal consistency loss to ensure the data fidelity of anatomical structures in the image domain and introduce the linear interpolation sinogram as prior knowledge to guide sinogram decomposition. NSD-Net, IR-Net, and F-Net are jointly trained so that they can benefit from one another. Extensive experiments on simulation and clinical data demonstrate that our method outperforms state-of-the-art MAR methods.

Designing an improved model of the adult female ICRP reference phantom dedicated to mammography procedure

Mammography is an x-ray-based imaging method to examine breast abnormalities. Since low-energy photons are used in mammography, doses to different organs would depend strongly on the phantom posture and anatomy. Until now, a few studies have been performed on doses delivered to different organs during mammography. However, in none of them, the correct posture of the patient has been considered. In the present study, the effect of accurate patient positioning, on doses to organs in the chest region were investigated through Monte Carlo simulations. The results show the rotation of the phantom head, may affect organ doses up to 60%. Also, ignoring the head in dosimetry calculations changes scattering effects and causes dose uncertainty of about 8% for these organs. Moreover, according to the obtained results, not compressing the breast causes serious dose misestimation. Finally, using developed phantoms dedicated for mammography, total doses received by different organs have been calculated for the tube voltages of 25, 28, 30 and 35 kVp and for craniocaudal and mediolateral oblique views.

Digital phantom versus patient-specific radiation dosimetry in adult routine thorax CT examinations.

The aim of this study was to compare the organ doses assessed through a digital phantom-based and a patient specific-based dosimetric tool in adult routine thorax computed tomography (CT) examinations with reference to physical dose measurements performed in anthropomorphic phantoms. Two Monte Carlo based dose calculation tools were used to assess organ doses in routine adult thorax CT examinations. These were a digital phantom-based dosimetry tool (NCICT, National Cancer Institute, USA) and a patient-specific individualized dosimetry tool (ImpactMC, CT Imaging GmbH, Germany). Digital phantoms and patients were classified in four groups according to their water equivalent diameter (Dw). Normalized to volume computed tomography dose index (CTDIvol), organ dose was assessed for lungs, esophagus, heart, breast, active bone marrow, and skin. Organ doses were compared to measurements performed using thermoluminescent detectors (TLDs) in two physical anthropomorphic phantoms that simulate the average adult individual as a male (Alderson Research Labs, USA) and as a female (ATOM Phantoms, USA). The average percent difference of NCICT to TLD and ImpactMC to TLD dose measurements across all organs in both sexes was 13% and 6%, respectively. The average±1 standard deviation in dose values across all organs with NCICT, ImpactMC, and TLDs was±0.06 (mGy/mGy),±0.19 (mGy/mGy), and±0.13 (mGy/mGy), respectively. Organ doses decreased with increasing Dw in both NCICT and ImpactMC. Organ doses estimated with ImpactMC were in closer agreement to TLDs compared to NCICT. This may be attributed to the inherent property of ImpactMC methodology to generate phantoms that resemble the realistic anatomy of the examined patient as opposed to NCICT methodology that incorporates an anatomical discrepancy between phantoms and patients.

Comparison of experimental measurements and fast Monte Carlo simulations for typical set-ups in fluoroscopically-guided interventional procedures

PyMCGPU-IR is an application based on the Monte Carlo code MCGPU-IR that automatically retrieves procedure information from X-ray systems and medical worker positions from a tracking camera system. PyMCGPU-IR calculates personal dose equivalent values, doses in organs and effective dose values for both patient and medical staff in interventional radiology procedures and displays them visually. The code's main advantage lies in its time efficiency, enabling simulations in under 2 min with statistical uncertainties below 5% (k = 2).This study involved testing in a hospital room using an interventional X-ray system. A RANDO phantom simulated the patient, with passive dosimeters affixed to the back for measuring skin dose values. A PMMA slab phantom represented the operator, with passive and active dosimeters affixed to its front surface to measure Hp(10). The irradiation conditions were simulated with PyMCGPU-IR using voxelized geometries to represent both phantoms. Results demonstrate good agreement between PyMCGPU-IR simulations and measured patient skin dose values, with differences of up to 5% for mean skin dose and up to 14% for the peak skin dose. Concerning Hp(10) values on the operator phantom, PyMCGPU-IR calculated values fall within the uncertainty ranges of dosimeter measurements for most points. The highest Hp(10) discrepancy is 42%, which is acceptable when compared with the typical variability observed between active and passive personal dosimeters measurements in interventional radiology. The results demonstrate PyMCGPU-IR's satisfactory performance for patient and personal dosimetry, compared to existing solutions like commercial skin dose calculation software and personal physical dosimeters.

68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG.

Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of 68Ga-FAP-2286, present the first-to our knowledge-dosimetry analysis to date, and compare the agent with 18F-FDG and FAPI compounds. Methods: Patients were administered 219 ± 43 MBq of 68Ga-FAP-2286 and scanned after 60 min. Uptake was measured in up to 5 lesions per patient and within the kidneys, spleen, liver, and mediastinum (blood pool). Absorbed doses were evaluated using MIM Encore and OLINDA/EXM version 1.1 using the International Commission on Radiological Protection publication 103 tissue weighting factor. Results: Forty-six patients were imaged with 68Ga-FAP-2286 PET. The highest average uptake was seen in sarcoma, cholangiocarcinoma, and colon cancer. The lowest uptake was found in lung cancer and testicular cancer. The average SUVmax was significantly higher on 68Ga-FAP-2286 PET than on 18F-FDG PET in cholangiocarcinoma (18.2 ± 6.4 vs. 9.1 ± 5.0, P = 0.007), breast cancer (11.1 ± 6.8 vs. 4.1 ± 2.2, P < 0.001), colon cancer (13.8 ± 2.2 vs. 7.6 ± 1.7, P = 0.001), hepatocellular carcinoma (9.3 ± 3.5 vs. 4.7 ± 1.3, P = 0.01), head and neck cancer (11.3 ± 3.5 vs. 7.6 ± 5.5, P = 0.04), and pancreatic adenocarcinoma (7.4 ± 1.8 vs. 3.7 ± 1.0, P = 0.01). The total-body effective dose was estimated at 1.16E-02 mSv/MBq, with the greatest absorbed organ dose in the urinary bladder wall (9.98E-02 mGy/MBq). Conclusion: 68Ga-FAP-2286 biodistribution, dosimetry, and tumor uptake were similar to those of previously reported FAPI compounds. Additionally,68Ga-FAP-2286 PET had consistently higher uptake than 18F-FDG PET. These results are especially promising in the setting of small-volume disease and differentiating tumor from inflammatory uptake.

Dose verifications in several organs in abdominal computed tomography (CT) scan by using Al2O3 OSL dosimeters

The study investigated the dose of several organs in the computed tomography (CT) scan by using Al2O3 optically stimulated luminescent (OSL) dosimeters. The organs of right and left kidney, right pancreas, spleen and liver in an anthropomorphic human phantom were investigated for the dose received during the scan. The OSL dosimeters are embedded into custom-made wax and replace onto two selected slices of human body phantom where the selected organs are located. The phantom was scanned with by using adult abdomen protocol. The percentage differences of OSL doses reading compared to the previous study data and the international dose reference level (DRL). The doses obtained from OSL NanoDots® showed excellent agreement compared to XRQA film dosimeters with percentage differences within 5%. The doses measured by using OSL dosimeters in five organs were also within the range of the national DRL values by the Ministry of Health of Malaysia (MOH). These findings suggest that our results can be utilized to verify the doses received by internal organs during computed tomography abdomen protocols. The overall results indicated the suitability of OSL dosimeters for the indirect dose verification in the CT scan.

Estimation of maternal and foetal risk of radiation-induced cancer from a survey of computed tomography pulmonary angiography and ventilation/perfusion lung scanning for diagnosing pulmonary embolism during pregnancy.

While there are many papers on maternal and foetal radiation doses from computed tomography pulmonary angiography (CTPA) and ventilation/perfusion (V/Q) lung scanning examinations for diagnosing pulmonary embolism in pregnant patients, few have used clinical data to examine the patient lifetime attributable risk (LAR) of different cancer types. This paper aims to estimate the cancer risk from maternal radiation doses from CTPA and V/Q examinations and associated foetal doses. Dosimetric data were determined for 267 pregnant patients who received CTPA and/or V/Q examinations over 8 years. Organ and foetal doses were determined using software allowing patient size variations for CTPA and using two different activity-to-organ dose conversion methods for V/Q scans. The LAR of cancer incidence was estimated using International Commission on Radiological Protection (ICRP) modelling including estimates of detriment. Estimated total cancer incidence was 23 and 22 cases per 100,000 for CTPA and V/Q examinations, respectively, with detriment estimates of 18 and 20 cases. Cancer incidence was evenly divided between lung and breast cancer for CTPA with lung cancer being 80% of all cancer for V/Q. The median foetal doses were 0.03 mSv for CTPA and 0.29 mSv for V/Q. Significant differences in estimated foetal dose for V/Q scans were obtained by the two different methods used. The differences in dose between the modes of CTPA scan acquisition highlight the importance of optimisation. Maternal cancer incidence and detriment were remarkably similar for each examination. Optimisation of examinations is critical for low-dose outcomes, particularly for CTPA examination.